Acumen Pharmaceuticals Analyst Price Targets - Benzinga

SPY751.21 QQQ682.81+0.25%BTC/USD76,887.90+0.28%DIA516.86−0.48%GLD358.15−0.97%TLT81.67−0.08%

Premium Services

Acumen Pharmaceuticals Inc

ABOSNASDAQ

Trade with Public

Trade with Public

$0.2397

0.029614.09%

Last update: Nov 3, 4:35 AM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Acumen Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Acumen Pharmaceuticals (ABOS).

Price Target Range — 12 Quarters

Analyst Consensus — 6 Analysts

5Buy

1Hold

Consensus RatingBuy# Analysts6Avg. Consensus PT$6Upside to Avg. PT+2470.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 2, 2026	BTIG	Thomas Shrader	PT Cut	Buy	$8→$1
Oct 30, 2026	Citigroup	Geoff Meacham	Downgrade	Buy→Neutral	$5→$1
Sep 16, 2026	BTIG	Thomas Shrader	Maintained	Buy	$8
Sep 15, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$4→$5
Mar 26, 2026	BTIG	Thomas Shrader	Maintained	Buy	$8
Mar 16, 2026	BTIG	Thomas Shrader	PT Raise	Buy	$7→$8
Jan 27, 2026	BTIG	Thomas Shrader	PT Raise	Buy	$4→$7
Nov 18, 2025	B of A Securities	Geoff Meacham	PT Cut	Buy	$9→$8
Aug 25, 2025	B of A Securities	Geoff Meacham	PT Cut	Buy	$10→$9
Jun 17, 2025	Citigroup	Geoff Meacham	Initiate	Buy	$4
Mar 28, 2025	UBS	Colin Bristow	PT Cut	Buy	$6→$4
Mar 28, 2025	HC Wainwright & Co.	Andrew Fein	PT Cut	Buy	$15→$11
Nov 13, 2024	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$15
Oct 3, 2024	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$15
Aug 15, 2024	UBS	Colin Bristow	PT Cut	Buy	$14→$6
Aug 14, 2024	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$15
Jul 25, 2024	Citigroup	David Hoang	Initiate	Buy	$7
May 15, 2024	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$15
Mar 31, 2024	UBS	Colin Bristow	PT Cut	Buy	$15→$14
Mar 27, 2024	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$15

Analyst Ratings News

Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday

Analysts upgraded MHK and CRWD, downgraded PFSI, cut ABOS’s target, and raised targets for NRXP, REGN and NTSK.

Avi Kapoor

PRO
BTIG Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $1

BTIG analyst Thomas Shrader maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and lowers the price target from $8 to $1.

Benzinga Newsdesk

PRO
Citigroup Downgrades Acumen Pharmaceuticals to Neutral, Lowers Price Target to $1

Citigroup analyst Geoff Meacham downgrades Acumen Pharmaceuticals (NASDAQ:ABOS) from Buy to Neutral and lowers the price target from $5 to $1.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Acumen Pharmaceuticals, Maintains $8 Price Target

BTIG analyst Thomas Shrader reiterates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $8 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Acumen Pharmaceuticals, Maintains $8 Price Target

BTIG analyst Thomas Shrader reiterates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $8 price target.

Benzinga Newsdesk

Baker Hughes To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday

Avi Kapoor